Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells

Okamoto, Ken‐ichi; Saito, Yoshitaka; Ueda, Hinata; Narumi, Katsuya; Furugen, Ayako; Kobayashi, Masaki

doi:10.1002/bdd.2298

Cited by 2 publications

(2 citation statements)

References 12 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLC7A11 immunotargeted therapies-such as the SLC7A11-targeted DNA vaccination [108], a virus-like particle immunotherapy targeting the SLC7A11 protein [109], and an anti-SLC7A11 viral vaccine based on the bovine herpesvirus 4 vector [110]-also impede the progression of breast cancer by inhibiting SLC7A11. [103], GC [111], PC [112], GBM [113], LUAD [114]…”

Section: Therapeutic Approaches Of Slc7a11mentioning

confidence: 99%

The Role of SLC7A11 in Cancer: Friend or Foe?

Sun

et al. 2022

Cancers

View full text Add to dashboard Cite

SLC7A11 controls the uptake of extracellular cystine in exchange for glutamate at a ratio of 1:1, and it is overexpressed in a variety of tumours. Accumulating evidence has shown that the expression of SLC7A11 is fine-tuned at multiple levels, and plays diverse functional and pharmacological roles in tumours, such as cellular redox homeostasis, cell growth and death, and cell metabolism. Many reports have suggested that the inhibition of SLC7A11 expression and activity is favourable for tumour therapy; thus, SLC7A11 is regarded as a potential therapeutic target. However, emerging evidence also suggests that on some occasions, the inhibition of SLC7A11 is beneficial to the survival of cancer cells, and confers the development of drug resistance. In this review, we first briefly introduce the biological properties of SLC7A11, including its structure and physiological functions, and further summarise its regulatory network and potential regulators. Then, focusing on its role in cancer, we describe the relationships of SLC7A11 with tumourigenesis, survival, proliferation, metastasis, and therapeutic resistance in more detail. Finally, since SLC7A11 has been linked to cancer through multiple approaches, we propose that its contribution and regulatory mechanism require further elucidation. Thus, more personalised therapeutic strategies should be adapted when targeting SLC7A11.

show abstract

Section: Therapeutic Approaches Of Slc7a11mentioning

confidence: 99%

The Role of SLC7A11 in Cancer: Friend or Foe?

Sun

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In the context of anticancer research, an inhibitor of xCT that has been approved by FDA is sulfasalazine (SAS). SAS upregulates ROS via xCT inhibition leading to cell death [ 136 ]. In the exosome scenario, a link between xCT and immune checkpoint blockade (ICB) therapy has been proposed in melanoma patients [ 101 ].…”

Section: Extracellular Vesicles Drug Efflux and Membrane Transportersmentioning

confidence: 99%

Extracellular Vesicles and Cell Pathways Involved in Cancer Chemoresistance

Console

Scalise

2022

Life

View full text Add to dashboard Cite

Chemoresistance is a pharmacological condition that allows transformed cells to maintain their proliferative phenotype in the presence of administered anticancer drugs. Recently, extracellular vesicles, including exosomes, have been identified as additional players responsible for the chemoresistance of cancer cells. These are nanovesicles that are released by almost all cell types in both physiological and pathological conditions and contain proteins and nucleic acids as molecular cargo. Extracellular vesicles released in the bloodstream reach recipient cells and confer them novel metabolic properties. Exosomes can foster chemoresistance by promoting prosurvival and antiapoptotic pathways, affecting cancer stem cells and immunotherapies, and stimulating drug efflux. In this context, a crucial role is played by membrane transporters belonging to ABC, SLC, and P-type pump families. These proteins are fundamental in cell metabolism and drug transport in either physiological or pathological conditions. In this review, different roles of extracellular vesicles in drug resistance of cancer cells will be explored.

show abstract

Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells

Cited by 2 publications

References 12 publications

The Role of SLC7A11 in Cancer: Friend or Foe?

The Role of SLC7A11 in Cancer: Friend or Foe?

Extracellular Vesicles and Cell Pathways Involved in Cancer Chemoresistance

Contact Info

Product

Resources

About